Charles Berkman Sells 9,673 Shares of OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles Berkman sold 9,673 shares of OmniAb stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total transaction of $16,540.83. Following the transaction, the insider directly owned 392,700 shares of the company’s stock, valued at approximately $671,517. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

OmniAb Stock Performance

Shares of OABI stock opened at $1.71 on Friday. OmniAb, Inc. has a 12-month low of $1.22 and a 12-month high of $4.02. The company has a market capitalization of $246.17 million, a P/E ratio of -2.95 and a beta of 0.13. The business’s 50 day moving average is $1.88 and its two-hundred day moving average is $1.76.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a research note on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.67.

Institutional Investors Weigh In On OmniAb

Several large investors have recently made changes to their positions in the business. Osaic Holdings Inc. raised its holdings in shares of OmniAb by 214.4% during the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after buying an additional 9,716 shares during the period. AQR Capital Management LLC bought a new position in OmniAb in the 1st quarter worth approximately $25,000. BNP Paribas Financial Markets increased its holdings in shares of OmniAb by 92.5% during the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after purchasing an additional 10,438 shares during the period. Cerity Partners LLC raised its position in shares of OmniAb by 111.5% during the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after buying an additional 11,919 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in OmniAb by 96.6% in the fourth quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock worth $43,000 after purchasing an additional 11,369 shares during the period. Institutional investors and hedge funds own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.